• About us
• Contact

Advertisement

Organisation › Details

UCB Ventures

UCB Ventures is a €150 million strategic corporate venture fund established in 2017 to further strengthen UCB's ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. UCB Ventures invests in innovative therapeutics and technology platforms that are early stage and higher risk, in areas adjacent to or even beyond UCB's therapeutic focus on neurology/neurodegenerative diseases, immunology and muscular skeletal/bone health. UCB Ventures takes an active role in its portfolio companies, contributing expertise in drug discovery, development and operations. *

 

	Start	2017-01-01 established
	Group	UCB (Group)
	Industry	venture capital
	Industry 2	pharmaceutical
	Person	Whittaker, Erica (UCB 201806 VP + Head of UCB Ventures)
	City	n. a.
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	150,000,000 (fund size (2020) 2020-07-28)
		* Document for »About Section«: ExeVir Bio B.V.. (7/28/20). "Press Release: ExeVir Bio to Accelerate Development of New Treatment Conferring Broad Protection Against COVID-19. EUR23M Series A Financing to Advance Lead Novel Llama-derived Antibody into Clinical Trials". Leuven.
		Record changed: 2023-11-16

Advertisement

More documents for UCB (Group)

• [1] Ariceum Therapeutics GmbH. (5/11/23). "Press Release: UCB and Ariceum Therapeutics Sign a Strategic Research Collaboration to Discover New Modalities for the Treatment of Immune-related Diseases and Cancer". Berlin & Brussels....
• [2] UCB S.A.. (3/15/23). "Press Release: Aitia and UCB Announce Strategic Drug Discovery Collaboration in Huntington's Disease". Brussels & Somerville, MA....
• [3] UCB S.A.. (3/9/23). "Press Release: Cancer Research UK Signs Multi-Project Collaboration with UCB to Advance Oncology Antibody Candidates". Brussels & London....
• [4] UCB S.A.. (3/9/23). "Press Release: UCB’s Board of Directors Appoints Jonathan Peacock as New Chair". Brussels....
• [5] SpliceBio S.L.. (2/16/22). "Press Release: SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline". Barcelona....
• [6] UCB S.A.. (1/19/22). "Press Release: UCB to Acquire Zogenix". Brussels & Emeryville, CA....
• [7] UCB S.A.. (12/2/21). "Press Release: UCB Announces Global Partnership to Bring Disease-modifying Therapies to People Living with Parkinson’s Disease". Brussels....
• [8] UCB S.A.. (11/30/21). "Press Release: UCB and Chiesi Enter Global License Agreement for Zampilimab a Novel Monoclonal Antibody for Fibrotic Lung Diseases". Brussels & Parma....
• [9] Atbtherapeutics. (10/5/21). "Press Release: Atbtherapeutics Expands Leadership Team and Scientific Advisory Board with Pharmaceutical Industry Experts". Aye....
• [10] UCB S.A.. (1/13/21). "Press Release: UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy". Brussels & Atlanta, GA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.